Publication of Phase 1/2 MM1636 Trial Results Follows FDA Breakthrough Therapy Designation for IO102-IO103 in combination with an anti-PD-1 monoclonal antibody

New York, New York - [December 09, 2021]: IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel immune-modulating cancer therapies based on its T-win® technology, today announced the publication of results from its Phase 1/2 MM1636 Melanoma trial in Nature Medicine that can be found HERE.

These clinical data further expand upon the data originally presented in a late-breaking abstract at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 by Professor Inge Marie Svane, M.D., Copenhagen University Hospital, Herlev.

“This is really exciting clinical data,” said Professor Inge Marie Svane, M.D. “We saw a high response rate for this patient population, and I am very optimistic for the continued development of this new immunotherapeutic”.

“We are very pleased that the MM1636 study has been published in Nature Medicine,” said Mai-Britt Zocca, Ph.D., chief executive officer and founder at IO Biotech. “We believe our platform and product candidates may represent a paradigm shift in the management of cancer, and that they have potential to become cornerstones of the treatment regimens of multiple solid tumors. The publication of this data set in Nature Medicine is yet another milestone for our development strategy”.

Publication of the MM1636 trial results follows the grant of breakthrough therapy designation for the investigational combination of IO102-IO103 with an anti-PD-1 monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma by the U.S. Food and Drug Administration in December 2020.